By Fineline Cube Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced that it has entered into an exclusive licensing agreement with 1cBio, Inc., a US‑based biotech company, for the development, manufacture and commercialisation of OC‑3 in Mainland China, Hong Kong, Macau, Taiwan, and certain other countries in Southeast Asia. OC‑3 is a next‑generation, PARP1‑selective inhibitor in preclinical development and a potential best‑in‑class agent for cancers defective in DNA homologous recombination repair (HRR), including prostate, ovarian, breast and pancreatic cancers with known mutations in DNA repair genes such as BRCA1, BRCA2 or PALB2.
Deal Snapshot
| Item | Detail |
|---|---|
| Licensee | Lee’s Pharmaceutical Holdings Limited (LPHK; HKG: 0950) |
| Licensor | 1cBio, Inc. (US‑based biotechnology company) |
| Agreement Type | Exclusive license – development, manufacture and commercialisation |
| Territory | Mainland China, Hong Kong, Macau, Taiwan, and certain other Southeast Asian countries |
| Asset | OC‑3 – next‑generation PARP1‑selective inhibitor (preclinical) |
| Announcement Date | 9 September 2026 |
| Financial Terms | Upfront, milestone and royalty figures: Not disclosed |
Drug Profile & Mechanism of Action
- Molecule: OC‑3, a next‑generation PARP1‑selective inhibitor currently in preclinical development.
- Target: PARP1 (poly ADP‑ribose polymerase 1), an enzyme central to DNA single‑strand break repair; selective inhibition of PARP1 — sparing PARP2 — is designed to maximize synthetic‑lethal antitumor activity while mitigating the hematologic toxicity that has limited earlier, non‑selective PARP inhibitors.
- Therapeutic Rationale: Exploits synthetic lethality in tumors defective in DNA homologous recombination repair, where PARP1 blockade leaves cancer cells unable to repair DNA damage, leading to selective tumor cell death.
- Target Indications: Cancers with known mutations in DNA repair genes such as BRCA1, BRCA2 or PALB2 — including prostate, ovarian, breast and pancreatic cancers.
- Positioning: Potential best‑in‑class PARP1 inhibitor; comparative preclinical data versus marketed PARP inhibitors: Not disclosed.
Deal Terms & Development Pathway
- LPHK Responsibilities: GLP safety studies and manufacturing activities required to obtain regulatory approval for OC‑3 in the Territory.
- Supply Arrangement: The agreement includes a drug supply manufacturing arrangement between the parties, securing product supply for the licensed markets.
- 1cBio Retained Rights: 1cBio retains the right to access and use data generated under the Agreement for its planned Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA) — preserving a parallel US development path outside the licensed territory.
- Structure: A regionally bifurcated model in which the same GLP dataset supports both LPHK’s Greater China/Southeast Asia registrations and 1cBio’s US IND, reducing duplicative preclinical spend.
Market Impact & Outlook
- PARP Inhibitor Franchise: PARP inhibitors are established standards of care in BRCA‑mutated ovarian, breast, prostate and pancreatic cancers; a PARP1‑selective next‑generation agent targets the class’s key limitation — toxicity‑driven dose reduction — with potential tolerability advantages. Specific differentiation data: Not disclosed.
- Regional Oncology Demand: Greater China and Southeast Asia carry a substantial HRR‑deficient cancer burden, and genetic testing adoption is expanding, supporting addressable demand for precision oncology assets. Epidemiological figures: Not disclosed in the announcement.
- Portfolio Strategy: The license extends Lee’s Pharmaceutical’s (HKG: 0950) oncology pipeline with a preclinical‑stage, potentially best‑in‑class asset while retaining its established development and manufacturing role in the Territory.
- Cross‑Border Licensing Momentum: The deal exemplifies continued US–China biotech licensing activity in precision oncology, with 1cBio preserving US IND optionality while monetizing Asia rights.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the preclinical development of OC‑3, GLP safety study timelines, IND filing plans, regulatory approvals, and commercialisation expectations in the licensed Territory. Actual results may differ materially due to risks including preclinical-to-clinical translation, safety findings, regulatory requirements in China and the United States, manufacturing execution, and competitive dynamics in the PARP inhibitor class.-Fineline Info & Tech